High-resolution mass spectrometry for characterizing the metabolism of synthetic cannabinoid THJ-018 and its 5-fluoro analog THJ-2201 after incubation in human hepatocytes

Clinical Chemistry

Volumn 62, Issue 1, 2016, Pages 157-169

  Diao, Xingxing ^a   Wohlfarth, Ariane ^a   Pang, Shaokun ^b   Scheidweiler, Karl B ^a   Huestis, Marilyn A ^a  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^b MDS SCIEX   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABINOID; CARBOXYLIC ACID; GLUCURONIDE; HYDROFLUORIC ACID; NAPHTHALENE; THJ 018; THJ 2201; UNCLASSIFIED DRUG; VALERIC ACID;

ARTICLE; CARBONYLATION; CARBOXYLATION; CONJUGATE; DEALKYLATION; DEFLUORINATION; DEHYDRATION; DEHYDROGENATION; DRUG METABOLISM; GLUCURONIDATION; HALF LIFE TIME; HEPATIC CLEARANCE; HEPATIC EXTRACTION RATIO; HUMAN; HUMAN CELL; HYDROXYLATION; IN VITRO STUDY; INTRINSIC CLEARANCE; LIVER CELL; MASS SPECTROMETRY; METABOLIC STABILITY; OXIDATION; PLASMA PROTEIN BINDING; PREDICTION; CHEMICAL STRUCTURE; CHEMISTRY; METABOLISM; SYNTHESIS;

CANNABINOIDS; HEPATOCYTES; HUMANS; MASS SPECTROMETRY; MOLECULAR STRUCTURE;

EID: 84952681824     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2015.243535     Document Type: Article

References (40)

1. Castaneto MS, Gorelick DA, Desrosiers NA, Hartman RL, Pirard S, Huestis MA. Synthetic cannabinoids: epidemiology, pharmacodynamics, and clinical implications. Drug Alcohol Depend 2014;144:12-41.
2. Desrosiers NA, Lee D, Concheiro-Guisan M, Scheidweiler KB, Gorelick DA, Huestis MA. Urinary cannabinoid disposition in occasional and frequent smokers: is THC-glucuronide in sequential urine samples a marker of recent use in frequent smokers? Clin Chem 2014;60:361-72.
3. Hermanns-Clausen M, Kneisel S, Szabo B, Auwarter V. Acute toxicity due to the confirmed consumption of synthetic cannabinoids: clinical and laboratory findings. Addiction 2013;108:534-44.
4. Seely KA, Lapoint J, Moran JH, Fattore L. Spice drugs are more than harmless herbal blends: a review of the pharmacology and toxicology of synthetic cannabinoids. Prog Neuropsychopharmacol Biol Psychiatry 2012;39:234-43.
5. Uchiyama N, Shimokawa Y, Kawamura M, Kikura-Hanajiri R, Hakamatsuka T. Chem analysis of a benzofuran derivative, 2-(2-ethylaminopropyl) benzofuran (2-EAPB), eight synthetic cannabinoids, five cathinone derivatives, and five other designer drugs newly detected in illegal products. Forensic Toxicol 2014;32:266-81.
6. Shevyrin V, Melkozerov V, Nevero A, Eltsov O, Morzherin Y, Shafran Y. 3-Naphthoylindazoles and 2-naphthoylbenzoimidazoles as novel chemical groups of synthetic cannabinoids: chemical structure elucidation, analytical characteristics and identification of the first representatives in smoke mixtures. Forensic Sci Int 2014;242:72-80.
7. US Department of Justice. Schedules of controlled substances: temporary placement of three synthetic cannabinoids into Schedule I. Fed Regist 2015:5042-7.
8. Uchiyama N, Shimokawa Y, Matsuda S, Kawamura M, Kikura-Hanajiri R, Goda Y. Two new synthetic cannabinoids, AM-2201 benzimidazole analog (FUBIMINA) and (4-methylpiperazin-1-yl) (1-pentyl-1H-indol-3-yl) methanone (MEPIRAPIM), and three phenethylamine derivatives, 25H-NBOMe 3, 4, 5-trimethoxybenzyl analog, 25BNBOMe, and 2C-N-NBOMe, identified in illegal products. Forensic Toxicol 2014;32:105-15.
9. Drugs-Forum. 2014. https://drugs-forum.com/forum/showthread.php?t=231444&page=2 (Accessed December 2014).
10. National Institute of Health Sciences. Data Search System for New Psychoactive Substances. 2015. http://npsdb.nihs.go.jp/Search/Default-e.aspx (Accessed March 2015).
11. Chimalakonda KC, Seely KA, Bratton SM, Brents LK, Moran CL, Endres GW, et al. Cytochrome P450-mediated oxidative metabolism of abused synthetic cannabinoids found in K2/Spice: identification of novel cannabinoid receptor ligands. Drug Metab Dispos 2012;40:2174-84.
12. Sobolevsky T, Prasolov I, Rodchenkov G. Detection of urinary metabolites of AM-2201 and UR-144, two novel synthetic cannabinoids. Drug Test Anal 2012;4:745-53.
13. Desrosiers NA, Himes SK, Scheidweiler KB, Concheiro-Guisan M, Gorelick DA, Huestis MA. Phase I and II cannabinoid disposition in blood and plasma of occasional and frequent smokers following controlled smoked cannabis. Clin Chem 2014;60:631-43.
14. Wintermeyer A, Moller I, Thevis M, Jubner M, Beike J, Rothschild MA, Bender K. In vitro phase I metabolism of the synthetic cannabimimetic JWH-018. Anal Bioanal Chem 2010;398:2141-53.
15. Hutter M, Broecker S, Kneisel S, Auwarter V. Identification of the major urinary metabolites in man of seven synthetic cannabinoids of the aminoalkylindole type present as adulterants in 'herbal mixtures' using LCMS/MS techniques. J Mass Spectrom 2012;47:54-65.
16. Hutter M, Moosmann B, Kneisel S, Auwarter V. Characteristics of the designer drug and synthetic cannabinoid receptor agonist AM-2201 regarding its chemistry and metabolism. J Mass Spectrom 2013;48:885-94.
17. Zhu M, Zhang H, Humphreys WG. Drug metabolite profiling and identification by high-resolution mass spectrometry. J Biol Chem 2011;286:25419-25.
18. Diao X, Pang X, Xie C, Guo Z, Zhong D, Chen X. Bioactivation of 3-n-butylphthalide via sulfation of its major metabolite 3-hydroxy-NBP: mediated mainly by sulfotransferase 1A1. Drug Metab Dispos 2014;42:774-81.
19. Wohlfarth A, Castaneto MS, Zhu M, Pang S, Scheidweiler KB, Kronstrand R, Huestis MA. Pentylindole/pentylindazole synthetic cannabinoids and their 5-fluoro analogs produce different primary metabolites: metabolite profiling for AB-PINACA and 5FAB-PINACA. AAPS J 2015;17:660-77.
20. Harris CR, Brown A. Synthetic cannabinoid intoxication: a case series and review. J Emerg Med 2013;44:360-6.
21. Baranczewski P, Stanczak A, Sundberg K, Svensson R, Wallin A, Jansson J, et al. Introduction to in vitro estimation of metabolic stability and drug interactions of new chemical entities in drug discovery and development. Pharmacol Rep 2006;58:453-72.
22. Diao X, Deng P, Xie C, Li X, Zhong D, Zhang Y, Chen X. Metabolism and pharmacokinetics of 3-nbutylphthalide (NBP) in humans: the role of cytochrome P450s and alcohol dehydrogenase in biotransformation. Drug Metab Dispos 2013;41:430-44.
23. Deng P, You T, Chen X, Yuan T, Huang H, Zhong D. Identification of amiodarone metabolites in human bile by ultraperformance liquid chromatography/quadrupole time-of-flight mass spectrometry. Drug Metab Dispos 2011;39:1058-69.
24. Sohlenius-Sternbeck AK, Chelpin HV, Orzechowski A, Halldin MM. Metabolism of sameridine to monocarboxylated products by hepatocytes isolated from the male rat. Drug Metab Dispos 2000;28:695-700.
25. Grigoryev A, Savchuk S, Melnik A, Moskaleva N, Dzhurko J, Ershov M, et al. Chromatography-mass spectrometry studies on the metabolism of synthetic cannabinoids JWH-018 and JWH-073, psychoactive components of smoking mixtures. J Chromatogr B Analyt Technol Biomed Life Sci 2011;879:1126-36.
26. Beckett AH. Metabolic oxidation of aliphatic basic nitrogen atoms and their alpha-carbon atoms. Xenobiotica 1971;1:365-83.
27. Ding J, Chen X, Gao Z, Dai X, Li L, Xie C, et al. Metabolism and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor apatinib in humans. Drug Metab Dispos 2013;41:1195-210.
28. Uldam HK, Juhl M, Pedersen H, Dalgaard L. Biosynthesis and identification of an N-oxide/N-glucuronide metabolite and first synthesis of an N-O-glucuronide metabolite of Lu AA21004. Drug Metab Dispos 2011;39:2264-74.
29. Ibrahim H, Couderc F, Perio P, Collin F, Nepveu F. Behavior of N-oxide derivatives in atmospheric pressure ionization mass spectrometry. Rapid Commun Mass Spectrom 2013;27:621-8.
30. Ismail IM, Dear GJ, Roberts AD, Plumb RS, Ayrtont J, Sweatman BC, Bowers GD. N-O glucuronidation: a major human metabolic pathway in the elimination of two novel anti-convulsant drug candidates. Xenobiotica 2002;32:29-43.
31. McNaney CA, Drexler DM, Hnatyshyn SY, Zvyaga TA, Knipe JO, Belcastro JV, Sanders M. An automated liquid chromatography-mass spectrometry process to determine metabolic stability half-life and intrinsic clearance of drug candidates by substrate depletion. Assay Drug Dev Technol 2008;6:121-9.
32. Lave T, Dupin S, Schmitt C, Valles B, Ubeaud G, Chou RC, et al. The use of human hepatocytes to select compounds based on their expected hepatic extraction ratios in humans. Pharmaceut Res 1997;14:152-5.
33. T'Jollyn H, Boussery K, Mortishire-Smith RJ, Coe K, De Boeck B, Van Bocxlaer JF, Mannens G. Evaluation of three state-of-the-art metabolite prediction software packages (Meteor, MetaSite, and StarDrop) through independent and synergistic use. Drug Metab Dispos 2011;39:2066-75.
34. Gandhi AS, Zhu M, Pang S, Wohlfarth A, Scheidweiler KB, Liu HF, Huestis MA. First characterization of AKB-48 metabolism, a novel synthetic cannabinoid, using human hepatocytes and high-resolution mass spectrometry. AAPS J 2013;15:1091-8.
35. Wohlfarth A, Pang SK, Zhu MS, Gandhi AS, Scheidweiler KB, Liu HF, Huestis MA. First metabolic profile of XLR-11, a novel synthetic cannabinoid, obtained by using human hepatocytes and high-resolution mass spectrometry. Clin Chem 2013;59:1638-48.
36. Wohlfarth A, Gandhi AS, Pang S, Zhu M, Scheidweiler KB, Huestis MA. Metabolism of synthetic cannabinoids PB-22 and its 5-fluoro analog, 5F-PB-22, by human hepatocyte incubation and high-resolution mass spectrometry. Anal Bioanal Chem 2014;406:1763-80.
37. Scheidweiler KB, Huestis MA. Simultaneous quantification of 20 synthetic cannabinoids and 21 metabolites, and semi-quantification of 12 alkyl hydroxy metabolites in human urine by liquid chromatographytandem mass spectrometry. J Chromatogr A 2014;1327:105-17.
38. Li XD, Xia SQ, Lv Y, He P, Han J, Wu MC. Conjugation metabolism of acetaminophen and bilirubin in extrahepatic tissues of rats. Life Sci 2004;74:1307-15.
39. Gao C, Zhang H, Guo Z, You T, Chen X, Zhong D. Mechanistic studies on the absorption and disposition of scutellarin in humans: selective OATP2B1-mediated hepatic uptake is a likely key determinant for its unique pharmacokinetic characteristics. Drug Metab Dispos 2012;40:2009-20.
40. Xie C, Zhou J, Guo Z, Diao X, Gao Z, Zhong D, et al. Metabolism and bioactivation of famitinib, a novel inhibitor of receptor tyrosine kinase, in cancer patients. Br J Pharmacol 2013;168:1687-706.